{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.0","upperLimit":"34.5","value":"26.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"}],"units":"Participants"}],"description":"Overall survival time (OS) was also evaluated and was defined as the duration of time from start of treatment to time of death up to 93 months, regardless of the cause of death. Medians are calculated from the Kaplan-Meier estimates and 95% confidence intervals, using Greenwood's standard error estimate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients in the four initial cohorts are combined in the efficacy presentations. Patients start once daily oral treatment of BIBW 2992 (Afatinib) at 50 mg before protocol amendment 2 (17 Dec 2008), until progression or undue adverse events (AEs) development. Patients can be dose-reduced up to two times if needed after temporary interruption of treatment due to drug- related AEs. After protocol amendment 2, the starting dose of BIBW 2992 was reduced to 40 mg, with 2 possible dose reductions if needed after temporary dose interruption due to drug-related AEs.","id":"OG000","title":"Afatinib"}],"paramType":"MEDIAN","populationDescription":"Treated set","reportingStatus":"POSTED","timeFrame":"Start of treatment to time to all death, up to 93 months","title":"Overall Survival Time","type":"SECONDARY","unitOfMeasure":"Months"}